Cyclooxygenase-2: From Arthritis Treatment to New Indications for Prevention and Treatment of Cancer: What Every Oncology Nurse Should Know

2.50
Hdl Handle:
http://hdl.handle.net/10755/165546
Category:
Abstract
Type:
Presentation
Title:
Cyclooxygenase-2: From Arthritis Treatment to New Indications for Prevention and Treatment of Cancer: What Every Oncology Nurse Should Know
Author(s):
Yamamoto, Deanna
Author Details:
Deanna Yamamoto, Santa Clara Valley Medical Center, San Jose, California, USA
Abstract:
Prostaglandins are created from arachidonic acid by the action of cyclooxygenase and subsequent synthetases. Two related forms of cyclooxygenase have been discovered which are now identified as COX-1 and COX-2. Although both isoenzymes change arachidonic acid to prostaglandins, they are different in their distribution and physiological role in the body. The revolutionary discovery of the isoenzymes cyclooxygenase 1 and 2 (COX-1 & COX-2) led to the development of newer non-steroidal anti-inflammatory drugs (NSAIDs) such as rofecoxib and celecoxib. Because of the specificity of COX-2 expression, the COX-2 inhibitors have the potential to reduce the risk of gastrointestinal bleeding such as experienced with the use of classic NSAIDs. With their crucial role in control of inflammation, the COX-2 agents were originally marketed for the treatment of rheumatoid and osteoarthritis. However, exciting new indications for COX-2 agents in the prevention and treatment of cancer are under investigation. The role of aberrant COX-2 expression in the development of cancer has been most widely studied in colon cancer and adenomas. Recent studies suggest that COX-2 derived prostaglandins may play an important role in tumor viability, growth, and control of metastasis. Possible new indications for the use of COX-2 inhibitors to prevent and possibly treat various cancers may be monumental. However, therapy with these agents is not totally without risk. Every oncology nurse should be aware of the possible problems inherent in the use of these drugs and the use of COX-2 agents for chemoprevention in certain cancers.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2002
Conference Name:
27th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Washington, D.C., USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleCyclooxygenase-2: From Arthritis Treatment to New Indications for Prevention and Treatment of Cancer: What Every Oncology Nurse Should Knowen_GB
dc.contributor.authorYamamoto, Deannaen_US
dc.author.detailsDeanna Yamamoto, Santa Clara Valley Medical Center, San Jose, California, USAen_US
dc.identifier.urihttp://hdl.handle.net/10755/165546-
dc.description.abstractProstaglandins are created from arachidonic acid by the action of cyclooxygenase and subsequent synthetases. Two related forms of cyclooxygenase have been discovered which are now identified as COX-1 and COX-2. Although both isoenzymes change arachidonic acid to prostaglandins, they are different in their distribution and physiological role in the body. The revolutionary discovery of the isoenzymes cyclooxygenase 1 and 2 (COX-1 & COX-2) led to the development of newer non-steroidal anti-inflammatory drugs (NSAIDs) such as rofecoxib and celecoxib. Because of the specificity of COX-2 expression, the COX-2 inhibitors have the potential to reduce the risk of gastrointestinal bleeding such as experienced with the use of classic NSAIDs. With their crucial role in control of inflammation, the COX-2 agents were originally marketed for the treatment of rheumatoid and osteoarthritis. However, exciting new indications for COX-2 agents in the prevention and treatment of cancer are under investigation. The role of aberrant COX-2 expression in the development of cancer has been most widely studied in colon cancer and adenomas. Recent studies suggest that COX-2 derived prostaglandins may play an important role in tumor viability, growth, and control of metastasis. Possible new indications for the use of COX-2 inhibitors to prevent and possibly treat various cancers may be monumental. However, therapy with these agents is not totally without risk. Every oncology nurse should be aware of the possible problems inherent in the use of these drugs and the use of COX-2 agents for chemoprevention in certain cancers.en_GB
dc.date.available2011-10-27T12:20:37Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:20:37Z-
dc.conference.date2002en_US
dc.conference.name27th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationWashington, D.C., USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.